Literature DB >> 12701806

Methyl group deficiency and guanidino production in uremia.

Burton D Cohen1.   

Abstract

Guanidinosuccinic acid (GSA) is one of the earliest uremic toxins isolated and its toxicity identified. Its metabolic origins have remained obscure until recently when a series of studies showed that it arose from the oxidation of argininosuccinic acid (ASA) by free radicals. The stimulus for this oxidation, occurring optimally in the presence of the failed kidney, is the rising level of urea which, through enzyme inhibition, results in a decline in hepatic levels of the semi-essential amino acid, arginine. It is further noted that concentrations of GSA in both serum and urine decline sharply in animals and humans exposed to the essential amino acid, methionine. In this review the argument is advanced that uremics suffer from a defective ability to generate methyl groups due to anorexia, dietary restrictions and renal protein leakage. This leads to the accumulation of homocysteine, a substance known to produce vascular damage. Even in healthy subjects intake of choline together with methionine is insufficient to satisfy total metabolic requirements for methyl groups. In end-stage renal disease, therefore, protein restriction contributes to the build-up of toxins in uremia. Replacement using specific amino acid mixtures should be directed toward identified deficiencies and adequacy monitored by following serum levels of the related toxins, in this case GSA and homocysteine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12701806

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  Left ventricular function in terminal uremia. A hemodynamic and echocardiographic study.

Authors:  H Acquatella; M Pérez-Rojas; B Burger; A Guinand-Baldó
Journal:  Nephron       Date:  1978       Impact factor: 2.847

2.  Role of reactive oxygen and argininosuccinate in guanidinosuccinate synthesis in isolated rat hepatocytes.

Authors:  K Aoyagi; S Nagase; M Gotoh; K Akiyama; M Satoh; A Hirayama; A Koyama
Journal:  Enzyme Protein       Date:  1996

3.  Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters.

Authors:  M M Avram; R Sreedhara; P Fein; K K Oo; J Chattopadhyay; N Mittman
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

4.  Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia.

Authors:  B Manns; E Hyndman; E Burgess; H Parsons; J Schaefer; F Snyder; N Scott-Douglas
Journal:  Kidney Int       Date:  2001-03       Impact factor: 10.612

5.  Factors affecting serum and urinary guanidinosuccinic acid levels in normal and uremic subjects.

Authors:  J D Kopple; S I Gordon; M Wang; M E Swendseid
Journal:  J Lab Clin Med       Date:  1977-08

6.  Further studies on the platelet-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding.

Authors:  H I Horowitz; I M Stein; B D Cohen; J G White
Journal:  Am J Med       Date:  1970-09       Impact factor: 4.965

7.  Guanidinosuccinic acid in uremia.

Authors:  B D Cohen
Journal:  Arch Intern Med       Date:  1970-11

8.  Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients.

Authors:  C van Guldener; M J Janssen; K de Meer; A J Donker; C D Stehouwer
Journal:  J Intern Med       Date:  1999-02       Impact factor: 8.989

9.  Inhibition of arginine synthesis by urea: a mechanism for arginine deficiency in renal failure which leads to increased hydroxyl radical generation.

Authors:  Kazumasa Aoyagi
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

10.  Defective ADP-induced platelet factor 3 activation in uremia.

Authors:  H I Horowitz; B D Cohen; P Martinez; M F Papayoanou
Journal:  Blood       Date:  1967-09       Impact factor: 22.113

View more
  3 in total

1.  Sex-Specific Metabolic Effects of Dietary Folate Withdrawal in Wild-Type and Aldh1l1 Knockout Mice.

Authors:  Jaspreet Sharma; Blake R Rushing; Madeline S Hall; Kristi L Helke; Susan L McRitchie; Natalia I Krupenko; Susan J Sumner; Sergey A Krupenko
Journal:  Metabolites       Date:  2022-05-18

2.  SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation.

Authors:  Takafumi Toyohara; Takehiro Suzuki; Ryo Morimoto; Yasutoshi Akiyama; Tomokazu Souma; Hiromi O Shiwaku; Yoichi Takeuchi; Eikan Mishima; Michiaki Abe; Masayuki Tanemoto; Satohiro Masuda; Hiroaki Kawano; Koji Maemura; Masaaki Nakayama; Hiroshi Sato; Tsuyoshi Mikkaichi; Hiroaki Yamaguchi; Shigefumi Fukui; Yoshihiro Fukumoto; Hiroaki Shimokawa; Ken-ichi Inui; Tetsuya Terasaki; Junichi Goto; Sadayoshi Ito; Takanori Hishinuma; Isabelle Rubera; Michel Tauc; Yoshiaki Fujii-Kuriyama; Hikaru Yabuuchi; Yoshinori Moriyama; Tomoyoshi Soga; Takaaki Abe
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

3.  Premature aging in uremia.

Authors:  Burton D Cohen
Journal:  Mol Cell Biochem       Date:  2006-11-29       Impact factor: 3.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.